Motohashi Shinya, Matsuo Takefumi, Inoue Hidenori, Kaneko Makoto, Shindo Shunya
1 Department of Cardiovascular Surgery, Hachioji Medical Center, Tokyo Medical University, Hachioji, Japan.
2 Hyogo Prefectural Awaji Medical Center, Sumoto, Japan.
Clin Appl Thromb Hemost. 2018 Sep;24(6):944-949. doi: 10.1177/1076029617734308. Epub 2017 Oct 18.
Heparin-induced thrombocytopenia (HIT) is one of the serious complications in patients who undergo cardiac surgery. However, there remains a major problem in diagnosing HIT because the current immunological assays for detection of HIT antibody have limitations. Furthermore, the clinical course of thrombocytopenia in this surgery makes it increasingly difficult to diagnose HIT. We investigated the relationship between platelet count and HIT antibody in 59 patients who underwent cardiac surgery using cardiopulmonary bypass (CPB). The number of postoperative HIT antibody-positive patients evaluated using enzyme-linked immunosorbent assay kit (polyanion IgG/IgA/IgM complex antibodies/antiplatelet factor 4 enhanced) was 37 (62.7%). In contrast, platelet activation by HIT antibody was evaluated using the serotonin release assay (SRA). More than 20% and 50% release of serotonin was obtained from 12 patients (20.3%) and 8 patients (13.6%), respectively. The levels of d-dimer were significantly different on postoperative day 14 between SRA-positive and SRA-negative groups; however, postoperative thrombus complication was not detected using sonography in the patients with positive serotonin release at all. After being decreased by the operation, their platelet count recovered within 2 weeks in both groups equally. In our study, although the patients were positive in the platelet activating HIT antibody assay, they remained free from thrombosis and their platelet count recovered after early postoperative platelet decrease. Therefore, in addition to the SRA, monitoring of platelet count might be still considered an indispensable factor to facilitate the prediction of HIT thrombosis prior to manifestation in the patients undergoing cardiac surgery using CPB.
肝素诱导的血小板减少症(HIT)是心脏手术患者的严重并发症之一。然而,HIT的诊断仍然存在一个主要问题,因为目前用于检测HIT抗体的免疫测定法存在局限性。此外,该手术中血小板减少的临床过程使得HIT的诊断越来越困难。我们调查了59例接受体外循环(CPB)心脏手术患者的血小板计数与HIT抗体之间的关系。使用酶联免疫吸附测定试剂盒(聚阴离子IgG/IgA/IgM复合物抗体/抗血小板因子4增强型)评估的术后HIT抗体阳性患者数量为37例(62.7%)。相比之下,使用血清素释放试验(SRA)评估HIT抗体引起的血小板活化。分别从12例患者(20.3%)和8例患者(13.6%)中获得了超过20%和50%的血清素释放。SRA阳性组和SRA阴性组术后第14天的D-二聚体水平存在显著差异;然而,在血清素释放呈阳性的患者中,超声检查未发现术后血栓并发症。两组患者术后血小板计数均在术后2周内同等程度地恢复,尽管手术使其降低。在我们的研究中,尽管患者在血小板活化HIT抗体检测中呈阳性,但他们没有发生血栓形成,并且在术后早期血小板减少后血小板计数恢复。因此,除了SRA之外,血小板计数监测可能仍然被认为是在接受CPB心脏手术的患者中预测HIT血栓形成发生之前的一个不可或缺的因素。